Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1026706 in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Trial)
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs BI 1026706 (Primary)
- Indications Osteoarthritis; Postoperative pain
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 26 Jan 2017 Status changed from not yet recruiting to completed.
- 01 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
- 01 Jun 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2016.